Clinical Trial Update: Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma [Phase 1]

View source ↗

Summary

Phase I trial evaluating panobinostat (HDAC inhibitor) with ipilimumab in unresectable stage III/IV melanoma completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Panobinostat (Panobinostat)
• ipilimumab (ipilimumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma, Skin Cancer | Phase 1 | Status: COMPLETED | Results posted: 2019-07-02